1-3 of 3
Patrick R. Conlon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Dorin Toader, Shawn P. Fessler, Scott D. Collins, Patrick R. Conlon, Reddy Bollu, Kalli C. Catcott, Chen-Ni Chin, Anouk Dirksen, Bingfan Du, Jeremy R. Duvall, Stacy Higgins, Mariya V. Kozytska, Kamela Bellovoda, Chelsey Faircloth, David Lee, Fu Li, Liuliang Qin, Caitlin Routhier, Pamela Shaw, Cheri A. Stevenson, Jason Wang, Phonphimon Wongthida, Elena Ter-Ovanesyan, Elizabeth Ditty, Stephen P. Bradley, Ling Xu, Mao Yin, Alexandr V. Yurkovetskiy, Rebecca Mosher, Marc Damelin, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (9): 999–1012.
https://doi.org/10.1158/1535-7163.MCT-22-0786
Published: 05 September 2023
View article titled, Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
Open the PDF for Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer in another window
Includes: Supplementary data
Journal Articles

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovanesyan, Charlie Bu, Alex J. Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxiu Zhang, Peter U. Park, Donald A. Bergstrom, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (5): 885–895.
https://doi.org/10.1158/1535-7163.MCT-20-0166
Published: 01 May 2021
View article titled, Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Open the PDF for Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect in another window
Includes: Supplementary data
Journal Articles

The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy, Mao Yin, Charlie Bu, Patrick R. Conlon, Damon R. Demady, Michael J. DeVit, Dmitry R. Gumerov, Venu R. Gurijala, Winnie Lee, Dennis McGillicuddy, Peter U. Park, Laura L. Poling, Marina Protopova, LiuLiang Qin, Cheri A. Stevenson, Elena Ter-Ovanesyan, Alex Uttard, Dongmei Xiao, Jian Xu, Ling Xu, Donald A. Bergstrom, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (5): 896–905.
https://doi.org/10.1158/1535-7163.MCT-20-0183
Published: 01 May 2021
View article titled, The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Open the PDF for The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b in another window
Includes: Supplementary data